Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131‐labeled lipiodol

• Published in: Cancer 1992-01, Vol.69 (2), p.346-352
• Main Authors: Raoul, J. I., Bretagne, J. F., Caucanas, J. P., Pariente, E. A., Boyer, J., Paris, J. C., Michel, H., Bourguet, P., Victor, G., Therain, F., Lejeune, J. J., Lemaire, B., Collet, H., Duvauferrier, R., Puech, J. L., Viala, J. F., L'Hoste, P., Poisonnier, M., Guiry, P.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological Availability; Carcinoma, Hepatocellular - diagnostic imaging; Carcinoma, Hepatocellular - radiotherapy; Female; Humans; Injections, Intra-Arterial; Iodine Radioisotopes - administration & dosage; Iodine Radioisotopes - pharmacokinetics; Iodine Radioisotopes - therapeutic use; Iodized Oil - administration & dosage; Iodized Oil - pharmacokinetics; Iodized Oil - therapeutic use; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - radiotherapy; Male; Middle Aged; Prospective Studies; Radionuclide Imaging; Radiotherapy - methods; Survival Analysis; Treatment Outcome
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19920115)69:2<346::AID-CNCR2820690212>3.0.CO;2-E

Preliminary Phase I trials have shown iodine 131 (131I)‐Lipiodol (ethiodized oil; Laboratoires Guerbet, Aulnay‐sous‐Bois, France) to be well tolerated and most likely effective in the treatment of hepatocellular carcinoma (HCC). In this multicenter Phase II trial, the authors tested the feasibility and reproducibility of this treatment in other medical institutions and evaluated its efficacy in 50 patients with unresectable Stage I or II HCC, by the classification of Okuda et al. The authors studied 47 men and 3 women (63.9 ± M 7.1 years old) with Stage I (n = 18) or II (n = 32) HCC, by the classification of Okuda et al., which was verified by histologic findings (n = 25), cytologic findings (n = 11), or association of a tumor with alpha‐fetoprotein serum values greater than μg500 /tg/l (n = 14). This multicenter trial (1) confirmed that the 131I‐Lipiodol treatment is well tolerated; (2) showed that there is a high reproducibility of results with respect to other institutions and an objective tumor response in 40% of the cases; and (3) indicated the necessity of performing a randomized controlled study.